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Abstract:  
Objectives: 
To apply current NICE clinical practice guidelines to a hypothetical older patient with multi-
morbidity and life limiting illness; (2) consider how treatment choices could be influenced by 
NICE guidance specifically related to multimorbidity; and, (3) ascertain if such clinical practice 
guidelines describe how and when medication should be reviewed, reduced and stopped. 
 
Methods: 
Based upon common long-term conditions in older people, a hypothetical older patient was 
constructed. Relevant NICE guidelines were applied to the hypothetical patient to determine 
what medication should be initiated in three treatment models:  a new patient model, a 
treatment resistant model, and a last line model.  Medication complexity for each model was 
assessed according to the medication regimen complexity index (MRCI). 
 
Results: 
The majority of the guidelines recommended the initiation of medication in the hypothetical 
patient; if the initial treatment approach was unsuccessful, each guideline advocated the use 
of more medication – with the regimen becoming increasingly complex. In the new patient 
model, 4 separate medications (9 dosage units) would be initiated per day; for the treatment 
resistant model, 6 separate medications (15 dosage units); and, for the last line model, 11 
separate medications (20 dosage units). None of the guidelines used for the hypothetical 
patient discussed approaches to stopping medication. 
 
Conclusions: 
In a UK context, disease specific clinical practice guidelines routinely advocate the initiation of 
medication to manage long-term conditions, with medication regimens becoming increasingly 
  
complex through the different steps of care. There is often a lack of information regarding 
specific treatment recommendations for older people with life limiting illness and multi-
morbidity. While guidelines frequently explain how and when a medication should be 
initiated, there is often no information concerning when the medications should be reduced 
or stopped. 
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Background:  
  
Clinical practice guidelines are described as systematically developed statements to 
assist professional decisions about appropriate healthcare for specific clinical 
circumstances.[1] They are used to provide support and advice to practitioners regarding a 
wide range of clinical situations, including patient monitoring, lifestyle advice, treatment 
choice through stepped care, and therapeutic drug monitoring. The use of clinical practice 
guidelines has become a common feature in modern day medicine, with many clinical 
decisions informed by them on a daily basis. Using clinical practice guidelines to inform 
treatment decisions has the advantage of improving the consistency of care in an attempt to 
improve overall health outcomes for patients.[2] This is critical, as studies have shown that 
treatment decisions for patients can vary dramatically depending on their clinician, hospital, 
or geographical region.[3] 
  In view of this, the number of clinical practice guidelines used in medicine is 
exponentially increasing: in 1990 there were around 70 guideline entries listed on PubMed 
and, by 2012, this number grew to over 7500.[4] Within England (and for some guidelines, 
Wales, Scotland, and Northern Ireland), these guidelines are provided by the National 
Institute for Health and Care Excellence (NICE), which has the overarching aim of providing 
‘gold standard’ cost effective guidance to optimise healthcare within the National Health 
Service (NHS). There are many stages involved in the process of NICE guideline development: 
topic choice, scope, evidence review, and consultation are all key steps. Critically, the 
recommendations from each NICE guideline are put together by subject specialists, 
practitioners, commissioners, and service users. NICE was first established in 1999, as the 
National Institute of Clinical Excellence; as more focus was placed on guideline utilisation, the 
scope of NICE was later broadened to include guidance around public health and social 
care.[5] 
 While the benefits of clinical practice guidelines have been well documented,[6] their 
utility has also been questioned – with some authors stating we should move away from a 
  
guideline driven approach and embrace shared-decision-making to ensure patients are cared 
for and considered as individuals.[7] Indeed, since the modern age of guidelines first began in 
the early nineties the world has changed: people are now living longer, and the number of 
people living with multiple co-existing long term conditions is increasing.[8-10] In response to 
these challenges, in addition to disease specific guidelines, NICE have recently developed a 
guideline specifically for multimorbidity.[11] 
In terms of prescribing medication – which many guidelines are centred upon – there 
are a number of challenges for older people: physiological changes brought about through the 
normal ageing process, as well as diseases associated with ageing (e.g. reduced hepatic blood 
flow, or an altered lean body mass) can affect the absorption, distribution, metabolism and 
excretion (ADME) properties of a drug.[12] These challenges are further compounded in 
multimorbidity, and life limiting illness situations, where older people are frequently 
prescribed multiple medications, resulting in polypharmacy.[13-14] Older people are 
therefore more likely to experience drug-drug interactions and adverse drug reactions, which 
could lead to potential harms.[15-16] Additionally, in people with a life limiting disease 
(typically with a prognosis of less than 12 months), patient goals of care can change from 
extending life and preventing disease to treating symptoms and optimising quality of life. As 
such, the risk: benefit ratio of medications may often change for an individual patient. It is 
critical that any clinical practice guideline advocating the prescribing of medication in older 
people reflects these challenges, and also explain how – and when – such medication should 
be reduced or stopped when it is no longer needed.  At present, despite the large number of 
clinical practice guidelines used to inform daily medical practice, it is unclear how such 
guidelines account for the challenges of ageing, multi-morbidity and life limiting illness in their 
treatment recommendations.[17-18]  
 This work, therefore, aimed to (1) apply disease specific NICE clinical practice 
guidelines to a hypothetical older patient with multi-morbidity and life limiting illness; (2) 
  
consider how treatment choices could be influenced by NICE guidance specifically related to 
multimorbidity; and, (3) ascertain if such clinical practice guidelines describe how and when 
medication should be reviewed, reduced and stopped. 
 
Method 
Hypothetical patient 
A hypothetical older female patient with stage IIIA non-small cell lung cancer was 
developed with the following long-term conditions: type 2 diabetes, hypertension, 
depression, and osteoarthritis. The hypothetical patient was aged 80 years, on the basis of 
the average life female expectancy in the UK being 82 years.[19] In addition, the five-year 
survival rate for stage IIIA non-small cell lung cancer is less than 10% to represent a patient 
with a clear limited life expectancy.[20] Lung cancer was chosen as the life limiting illness in 
our hypothetical patient because, in the developed world, it is the most common cause of 
cancer death for males and females.[21] The rationale for the choice of chronic conditions 
was based upon common conditions reported in the General Lifestyle Survey, and those 
included in the 2016 Quality Outcomes Framework.[22] A total of four long-term conditions 
were chosen, based upon the average number of long-term conditions reported in older 
people.[23-25]  
 
The patient’s initial parameters were set to the following to represent typical readings in an 
older person: 
Blood pressure:  160/90 mmHg  
Blood glucose: 14.9 mmol/L 
HbA1c:  97 mmol/mol 
QRISK2score: 42.2% 
 
  
The following disease specific NICE guidelines were used to inform treatment 
recommendations for the hypothetical patient in view of the long-term conditions:  
 Hypertension in adults: diagnosis and management [26] 
 Cardiovascular disease: risk assessment and reduction, including lipid modification 
[27] 
 Type 2 diabetes in adults: management [28] 
 Depression in adults: recognition and management [29] 
 Osteoarthritis: care and management [30] 
 
These specific guidelines were identified by searching the NICE guideline registry  
(https://www.nice.org.uk/guidance) for the five medical conditions in the hypothetical 
patient and selecting the most recent, and appropriate ones. 
 
In addition to the disease specific treatment guidelines, the treatment choices were also 
considered according to the Lung cancer: diagnosis and management [31] NICE guideline to 
ascertain if there was any specific advice in relation the treatment of long-term conditions in 
people with lung cancer. The Multimorbidity: clinical assessment and management NICE 
guideline [11] was also considered to ascertain how treatment choices could be influenced in 
our hypothetical patient. To mimic the stepped approach to patient care, as employed by 
clinical practice guidelines, each guideline was considered according to the following models: 
a new patient model (when the patient initially presents to the clinician without using any 
medication); a treatment resistant model (when the first-line therapy fails to control 
symptoms), and a last line model (the last step of therapy, where previous medications have 
failed to control symptoms). It was assumed that the hypothetical patient was adherent to 
treatment when moving between models. We only considered pharmacological intervention, 
  
and did not consider additional monitoring requirements or lifestyle changes in our analysis 
(e.g. blood glucose testing or diet control). 
 
Quality Appraisal and Data Extraction 
Each guideline was applied to the hypothetical patient to determine what medication, if 
any, should be initiated in view of the patient’s long-term conditions. The application of each 
guideline was done independently (by DO and AP) and, in the case of disagreement, consensus 
was reached with AT (senior author). Each guideline was independently data extracted, and 
appraised (DO and AP) according to the criteria previously proposed by Boyd and colleagues, 
as outlined below;[32] any disagreements in the appraisal were again reached by consensus 
(AT).  
 Do the guidelines address treatment for the type of patient? (older person, person 
with multi-morbidity)  
 Is the quality of evidence discussed for older adults/adults with multi-morbidity? 
 Is time needed to treat to benefit from treatment in the context of life expectancy 
discussed? 
 
In addition, to the above questions, a further three questions were posed to determine if the 
guidelines considered deprescribing in their recommendations; we defined deprescribing as 
the process of withdrawal of an inappropriate medication, supervised by a health professional 
with the goal of managing polypharmacy and improving outcomes, as proposed by Reeve and 
colleagues.[33] 
 Do the guidelines address deprescribing/stopping treatment? 
 Do the guidelines address when to deprescribe? 
 Do the guidelines address the process of deprescribing? 
Assessment of medication complexity 
  
The medication regimen complexity index (MRCI) was used to quantify the complexity of each 
medication regimen, based on the dosing requirements during a typical day.  The MRCI is a 
validated 65-instrument tool, and has three components:[34] 
 Dosage form – accounts for dosage form, and routes of administration. 
 Dosage frequency – accounts for how often the medication is to be administered 
during a typical day. 
 Additional instructions – accounts for specific instructions a patient must follow when 
taking the medication (e.g. taking the medication with food). 
 The sum of the three scores form an overall score of medication complexity.  Higher scores 
on the MRCI have been associated with reduced medication adherence levels,[35] unplanned 
hospital admissions [36], and increased mortality.[37] 
 
Results 
Medication regimen in the hypothetical patient according to disease specific guidelines 
Overall, five of the disease specific guidelines recommended the initiation of 
medication in the hypothetical patient; if the initial treatment approach was unsuccessful, 
each guideline advocated the use of more medication. One guideline, the Cardiovascular 
Disease guideline,[27] specifically stated that the decision to start statin therapy should be 
made after an informed discussion between the clinician and the patient about the risks and 
benefits of treatment, taking into account additional factors including informed patient 
preference, co-morbidities, polypharmacy and life expectancy. Given the limited life 
expectancy of our hypothetical patient, we interpreted the guideline that it would not be 
appropriate to initiate statin therapy. The lung cancer guidance[31] only contained 
information on approaches – in terms of chemotherapy selection – to manage the lung cancer, 
no consideration or reference was made to how long-term conditions should be managed in 
a patient with lung cancer.  
  
In the new patient model, a total of 4 separate medications – totalling 9 dosage units 
per day – would be initiated to manage the four long-term diseases; this increased to 6 
separate medications – totalling 15 dosage units per day in the treatment resistant model; in 
the last line model, this further increased to 11 separate medications – totalling 20 dosage 
units per day. The majority of the medications were taken to treat the symptoms associated 
with the long-term condition (e.g. a selective serotonin reuptake inhibitor to treat the 
symptoms of depression), or to prevent complications occurring in the future (e.g. using 
amlodipine to reduce blood pressure to reduce the risk of a myocardial infarction or ischaemic 
stroke). One medication, the omeprazole, was initiated to reduce the GI adverse effects 
associated with the aspirin – this was considered an important intervention, especially in view 
of the co-administration of sertraline, and the increased risk of bleeding. The initiation of 
gastroprotection was specifically recommended in the depression guideline,[29] and also in 
the osteoarthritis guideline[29] when systemic NSAIDs are indicated. For the different models 
of treatment, the MRCI scores increased alongside the different phases of treatment, showing 
that as treatment is stepped up, the complexity of the medication regimen also increases 
(Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Medication summary for the three treatment models in the hypothetical patient, 
based upon disease specific NICE guidelines.  
  
*Assume the sertraline is titrated to 200 mg, before switching to fluoxetine in the treatment resistant 
model.  
±Assume the metformin is titrated to 2 gram daily, before gliclazide is initiated. 
§Can be started in primary care in consultation with a consultant psychiatrist.  
 
Time New patient model Treatment resistant model Last line model 
8 am Amlodipine 5 mg tab 
Metformin 500 mg tab± 
Sertraline 50 mg tab* 
Paracetamol 500 mg tabs x 2 
 
Amlodipine 10 mg tab 
Metformin 500 mg tab x 2 
Fluoxetine 20 mg caps x 3 
Gliclazide 80 mg tab x 2 
Ramipril 10 mg cap 
Paracetamol 500 mg tabs x 
2 
Ibuprofen gel 
Amlodipine 10 mg tab 
Metformin 500 mg tab x 2 
Fluoxetine 20 mg caps x 3 
Omeprazole 20 mg cap 
Gliclazide 80 mg tab x 2 
Ramipril 10 mg cap 
Indapamide 2.5 mg tab 
Pioglitazone 80 mg tab 
Atenolol 50 mg tab 
Paracetamol 500 mg tabs x 
2 
Ibuprofen 400 mg tab 
1 pm Metformin 500 mg tab 
Paracetamol 500 mg tabs x 2 
 
Metformin 500 mg tab 
Paracetamol 500 mg tabs x 
2 
Ibuprofen gel 
 
Metformin 500 mg tab 
Paracetamol 500 mg tabs x 
2 
Ibuprofen 400 mg tab 
 
6 pm Metformin 500 mg tab 
Paracetamol 500 mg tabs x 2 
Metformin 500 mg tab 
Gliclazide 80 mg tab x2 
Paracetamol 500 mg tabs x 
2 
Ibuprofen gel 
Metformin 500 mg tabs 
Gliclazide 80 mg tabs x2 
Paracetamol 500 mg tabs x 
2 
Ibuprofen 400 mg tab 
  
10 pm Paracetamol 500 mg tabs x 2 
 
Paracetamol 500 mg tabs x 
2 
 
Paracetamol 500 mg tabs x 
2 
Mirtazapine 15 mg tab§ 
MRCI 
Score 
12 24 30 
 
Assessment of disease specific NICE guidelines  
All of the disease specific NICE guidelines used for our hypothetical patient 
(hypertension, depression, lipid modification, osteoarthritis and diabetes type 2) contained 
treatment recommendations for older people, as outlined in Table 2. The guidelines 
concerning lipid modification and diabetes type 2 considered limited life expectancy of the 
patient in their treatment recommendations, although the time until benefit of treatment was 
not considered in depth: for the lipid modification guideline, this consideration impacted on 
the decision to start the statin, while for the diabetes type 2 guideline, it increased the 
threshold to start or add in additional medication, by creating more conservative HbA1c 
targets.  Co-morbidity was mentioned briefly in the guidelines for hypertension [26] and lipid 
modification [27], while the term multi-morbidity was outlined within the diabetes type 2 
guideline, as part of an individualised care approach [28]: unfortunately, there were no cases 
where specific treatment recommendations were considered according to these terms. In our 
hypothetical patient, we did initiate medication (and also move between the different 
treatment stages by initiating additional medication) to manage the diabetes, although by 
creating more conservative HbA1c targets, it is possible that medication would be started in 
a lower proportion of lower older people; we also accept that depending on our Hb1AC 
targets, and the patients preferences, it may have been appropriate to not initiate therapy, or 
add in additional medications. The other NICE guidelines [26,29-31] did not consider 
treatment recommendations in the context of (limited) life expectancy – this included 
  
guidelines for the management of chronic disease (depression, hypertension), and the specific 
guidance for the treatment of lung cancer. Furthermore, none of the disease specific 
guidelines addressed the deprescribing of medication in their recommendations; this included 
when medication should be reviewed, reduced or stopped, or the process for how this could 
be achieved.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Examples of specific treatment recommendations from disease specific NICE 
guidelines in relation to older people 
 
NICE Guidance Comment from Guideline in relation to older people 
 
Depression 
 
SSRIs are associated with an increased risk of bleeding, especially in older 
people or in people taking other drugs that have the potential to damage the 
gastrointestinal mucosa or interfere with clotting. In particular, consider 
prescribing a gastroprotective drug in older people who are taking non-
steroidal anti-inflammatory drugs (NSAIDs) or aspirin  
 
  
 
Hypertension 
 
Offer people aged 80 years and over the same antihypertensive drug treatment 
as people aged 55–80 years, taking into account any comorbidities 
 
Aim for a target clinic blood pressure below 150/90 mmHg in people aged 80 
years and over, with treated hypertension 
 
 
Lipid Modification 
 
For people 85 years or older consider atorvastatin 20 mg as statins may be of 
benefit in reducing the risk of non-fatal myocardial infarction. Be aware of factors 
that may make treatment inappropriate. 
 
The decision whether to start statin therapy should be made after an informed 
discussion between the clinician and the person about the risks and benefits of 
statin treatment, taking into account additional factors such as potential benefits 
from lifestyle modifications, informed patient preference, comorbidities, 
polypharmacy, general frailty and life expectancy. 
 
 
Osteoarthritis 
 
If paracetamol or topical NSAIDs are insufficient for pain relief for people with 
osteoarthritis, then the addition of opioid analgesics should be considered. 
Risks and benefits should be considered, particularly in older people.  
 
 
Type 2 Diabetes 
 
When caring for older adults with type 2 diabetes, particular consideration 
should be given to their broader health and social care needs. Older people are 
more likely to have co-existing conditions and to be on a greater number of 
medicines. Their ability to benefit from risk-reduction interventions in the 
longer term may also be reduced.  
Consider relaxing the target HbA1c level on a case-by-case basis, with particular 
consideration for people who are older or frail, for adults with type 2 diabetes:  
 who are unlikely to achieve longer-term risk-reduction benefits, for 
example, people with a reduced life expectancy;  
 For whom tight blood glucose control poses a high risk of the 
consequences of hypoglycaemia, for example, people who are at risk 
of falling, people who have impaired awareness of hypoglycaemia, and 
people who drive or operate machinery as part of their job;  
 For whom intensive management would not be appropriate, for 
example, people with significant comorbidities.  
 
 
 
Assessment of multimorbidity NICE guideline 
  
The Multimorbidity: clinical assessment and management NICE guideline focused on how to 
optimise care for people with multimorbidity, and in stark contrast to the disease specific NICE 
guidelines, only outlined one medication specific recommendation, which related to 
bisphosphonate use (recommendation 1.6.16, page 12 [11]). The remaining 
recommendations were overarching principles of care, and included promoting shared 
decisions, and the importance of considering patients’ goals, values and priorities in treatment 
decisions. As the recommendations were overarching in nature, rather than medication 
specific, the quality of evidence for people with multimorbidity was not discussed or outlined. 
Similarly, although there was reference to people with life limiting illness in these overarching 
principles of care, there was no discussion of the quality of evidence in this regard. Several of 
the overarching principles were pertinent to treatment considerations in our hypothetical 
patient, as outlined in Table 3. If our hypothetical patient’s priorities of care were focused on 
acute symptom management, in view of the principles of care stated in this guideline, and the 
relatively long time to benefit of treatment, it could be interpreted that the medication used 
to treat hypertension, and diabetes would not have been initiated, although the guideline did 
not state this specifically. The multimorbidity guideline did not specifically recommend when 
or how to deprescribe medications, instead only providing a recommendation to discuss 
whether individuals wish to continue their medications. In addition, the NICE multimorbidity 
guideline did not make any reference to the five disease specific NICE guidelines that were 
utilised by our hypothetical patient; nor was there any reference to the multimorbidity 
guideline in the disease specific NICE guidelines, although we acknowledge the multimorbidity 
guideline was published after some of the disease-specific guidelines used in our hypothetical 
patient. 
 
Table 3: Principles of care from outlined in the NICE multimorbidity guideline in relation to 
older people 
  
Comment from guideline relevant to hypothetical patient  
 
 
Think carefully about the risks and benefits, for people with multimorbidity, of 
individual treatments recommended in guidance for single health conditions. 
Discuss this with the patient alongside their preferences for care and treatment.  
 
 
When offering an approach to care that takes account of multimorbidity, focus on: 
 
 how the person's health conditions and their treatments interact and how 
this affects quality of life 
 the person's individual needs, preferences for treatments, health 
priorities, lifestyle and goals 
 the benefits and risks of following recommendations from guidance on 
single health conditions 
 improving quality of life by reducing treatment burden, adverse events, 
and unplanned care 
 
 
Discuss with the person the purpose of the approach to care, that is, to improve 
quality of life. Take into account the possibility of lower overall benefit of continuing 
treatments that aim to offer prognostic benefit, particularly in people with limited 
life expectancy or frailty.  
 
 
Take into account the possibility of lower overall benefit of continuing treatments 
that aim to offer prognostic benefit, particularly in people with limited life 
expectancy or frailty.  
 
 
Discuss with people who have multimorbidity and limited life expectancy or frailty 
whether they wish to continue treatments recommended in guidance on single 
health conditions which may offer them limited overall benefit.  
 
 
Discuss any changes to treatments that aim to offer prognostic benefit with the 
person, taking into account:  
 their views on the likely benefits and harms from individual treatments 
 
 what is important to them in terms of personal goals, values and priorities  
 
 
Discussion:  
This is the first study to explore the appropriateness of UK guidelines regarding 
treatment recommendations for older people with multi-morbidity and limited life 
expectancy. We have identified four key findings that are of importance to healthcare 
practitioners and policy makers: (1) disease specific guidelines routinely advocate the 
initiation of medication to manage chronic conditions in older people, with medication 
  
regimens becoming increasing complex through the different steps of care; (2) although there 
is often information regarding the initiation of treatment in older people in disease specific 
guidelines, there is often a lack of detailed information regarding specific treatment 
recommendations for older people with life limiting illness and multi-morbidity; (3) in contrast 
to the disease specific guidelines, guidance specifically related to multimorbidity contains 
overarching principles that seek to optimise care, although such guidelines fall short of stating 
specific treatment recommendations (prescribing or depreprescribing) regarding medication; 
and, (4), current guidelines advocate the initiation of medication to manage long term 
conditions, without considering when and how these medications should be reviewed and 
stopped (deprescribed); this causes polypharmacy, which has potential to cause adverse drug 
events. Overall, when managing a complex older patient, the interplay between the disease 
specific guidelines and the multimorbity guideline are analogous to driving a car: the disease 
specific guidelines act as an accelerator pedal regarding treatment (by focusing on initiating 
medication), while the multimorbidity guideline acts as the break (by focusing on treatment 
optimisation). When these guidelines are used in tandem, a balance may be reached in 
regards to appropriate medication use; however, when disease specific guidelines are used in 
isolation, there is potential for the car to speed, with more focus on initiating (potentially 
inappropriate) medication. Given the need to keep disease specific guidelines concise (to 
optimise user friendliness) it may not be appropriate to include an in-depth discussion of 
multimorbidity and limited life expectancy in all disease specific guidelines, however, at a 
minimum they should refer to and signpost people to the multi-morbidity guideline. These 
are potentially important and significant findings given the ageing population and the 
exponential increase in the use of clinical practice guidelines to support clinicians in their 
decision-making.  
While this is the first study to examine the appropriateness of clinical practice 
guidelines in a UK context, other studies have explored the appropriateness of clinical practice 
  
guidelines in other settings. A seminal study by Boyd and colleagues evaluated the 
applicability of US clinical practice guidelines to the care of older individuals with several co-
morbid diseases.[32]  In agreement with our study, Boyd and colleagues showed that most 
disease specific clinical practice guidelines do not modify or discuss the applicability of their 
recommendations for older people with multiple co-morbidities. They also constructed a 
hypothetical patient with chronic obstructive pulmonary disease, type 2 diabetes, 
osteoporosis, hypertension and osteoarthritis, and showed that if the relevant clinical practice 
guidelines were followed, the patient would be prescribed 12 medications, costing over $400 
per month. Several other studies reviewing disease specific guidelines internationally have 
also found that there is a lack of information and guidance for managing older adults with 
multi-morbidity, especially in relation to treatment in the presence of dis-concordant co-
morbidities.[38,39]  
The lack of appropriateness of disease specific practice guidelines for older adults with 
multiple co-existing long-term conditions may not be directly attributed to guideline 
developers.[40] Protocols and guidance on clinical practice guideline development requires 
the use of high quality evidence, which in the case of treating long-term conditions is usually 
randomised controlled clinical trials.[41] It has been shown that older people and those with 
multi-morbidity are often excluded from clinical trials, meaning that the results may not be 
applicable to the general patient population.[42-43] In cases where older people are included 
in clinical trials, the results are often not reported or statistically interpreted according to age, 
although this limitation is acknowledged in some guidelines.[44] For example, the Heart 
Protection Study, a key study assessing the effectiveness of statin therapy in 20,536 high-risk 
individuals, only recruited people aged between 40 to 80 years.[45] As such, NICE specifically 
acknowledge in their guidance on Cardiovascular Disease that assessing the effectiveness of 
statin therapy in older people should be a research priority.[26] In contrast, there have been 
studies that explore the effectiveness of antihypertensive therapy in older people:[46] and as 
  
a consequence of this research, NICE specifically consider initiating antihypertensive 
medication according to age – with a higher threshold of treatment recommended for people 
aged over 80 years.[26] In keeping with this approach, the NICE multi-morbidity guideline, 
which seeks to optimise care for adults through a series of recommendations, uses terms such 
as “taking account of multi-morbidity in tailoring an approach to care”, and “how to identify 
people who may benefit”.[11] The approach of dealing with multimorbidity as a separate 
entity is a significant step forward since the work by Boyd and colleagues [32], but it is clear 
that more could be done to integrate these overarching principles of care into more practical 
and specific recommendations for disease-specific treatment guidelines. 
Guidelines often contain a disclaimer and may recommend shared decision-making 
between the healthcare professional and the patient to decide whether (or not) a medication 
should be initiated. We note, for example, that each of the NICE guidelines applied to our 
hypothetical patient stated:  
When exercising their judgement, professionals and practitioners are expected to take 
this guideline fully into account, alongside the individual needs, preferences and values 
of their patients or the people using their service. It is not mandatory to apply the 
recommendations, and the guideline does not override the responsibility to make 
decisions appropriate to the circumstances of the individual, in consultation with them 
and their families and carers or guardian  
While this is encouraging, medical practitioners have reported a fear of litigation if they do 
not follow guidelines.[47] For example, if a guideline recommendation for treatment is not 
followed, and harm occurs to a patient, they (or their family) may seek claims of negligence, 
and litigation, causing significant stress to the prescribing clinician.[48] Additionally, some 
health care systems include a “pay for performance” system whereby clinicians’ 
reimbursement for service may be influenced by their adherence to standards of care for 
single diseases. These standards of care are often extracted from guidelines (despite the 
  
guidelines not being developed for this purpose), and such systems disincentivise managing 
complex issues in people living with multiple co-existing long-term conditions.[32] The 
statement regarding statin therapy in the NICE Cardiovascular Disease guideline that 
treatment initiation should also consider additional factors, such as informed patient 
preference, polypharmacy and life expectancy, is helpful in this regard, and this was main 
reason why statin therapy was not initiated in our hypothetical patient. Recent trial evidence 
shows that statins can be discontinued in patients with limited life expectancy without causing 
negative outcomes for patients;[49] however, preventative medications, including statins, are 
routinely inappropriately prescribed to older patients with limited life expectancy.[50] 
In terms of once treatment was initiated, it was clear from our findings that none of 
the NICE clinical practice guidelines addressed how and when treatment should be stopped 
or discontinued – so called deprescribing. This finding is timely given the findings of Markovitz 
and colleagues who showed that guidelines for cardiovascular disease and diabetes primarily 
recommend intensification, rather than deintensification, of therapy.[17] Similarly, Jansen 
and colleagues, who reviewed cardiovascular guidelines, found that none included any 
information about when or how to stop medications, with one even encouraging against 
discontinuation.[51] In recent years, a great deal of attention has been given to the concept 
‘deprescribing’: the process of which has recently been outlined,[52] and studies suggest that 
deprescribing initiatives aimed at older people are feasible and safe and may improve health 
outcomes and reduce mortality.[53] In view of this and GP reports of a lack of guidelines as a 
significant barrier to deprescribing, there have been a number of medication specific 
deprescribing guidelines developed that consider when and how to reduce and stop 
medication.[54-56] These guidelines have been developed following the robust standards in 
which clinical practice guidelines are developed.[57]  Indeed, rather than separate out the 
process of initiating, monitoring, and deprescribing medication, we believe in order for the 
recent deprescribing guidelines to gain maximum utility, it is important that these 
  
deprescribing recommendations – or the principles of them – are included within disease 
specific clinical practice guidelines; or as a minimum, from a UK perspective, it would be 
helpful if NICE were to develop a separate deprescribing guideline, in a similar approach to 
the multimorbidity guideline, and make reference to it in disease specific guidelines. We 
acknowledge that it is challenging, especially considering the current models of care in general 
practice where GPs typically have 12 minutes for a patient consultation. One possible solution 
to dealing with complex older patients taking multiple medications is the recent introduction 
of clinical pharmacists working in general practice as part of the primary care team as part of 
a pilot by NHS England.[58] 
This work has several limitations. Firstly, we only considered guidelines underpinning 
treatment recommendations for four long-term conditions; it is possible that guidelines for 
other conditions include specific treatment recommendations for deprescribing medication 
in older people and, as such, may not be representative of all NICE guidelines. Secondly, we 
only considered the brief NICE guideline; the full supporting evidence used to formulate the 
guideline recommendations were not considered, even though they were available on the 
NICE website. The rationale for this approach was that each brief guideline contains circa 50 
pages, while the full guideline with all of the supporting evidence is circa 500 pages. We 
therefore believe it is unlikely that a clinician would have the time to read a 500-page guideline 
to inform their routine prescribing practice. However, it is possible that the supporting 
evidence of each of the guidelines contains information about prescribing medication to older 
people with multiple co-existing long-term conditions.  We therefore recommend that our 
findings are interpreted in view of these limitations. 
 
Conclusion 
In a UK context, disease specific clinical practice guidelines routinely advocate the 
initiation of medication to manage long-term conditions, with medication regimens becoming 
  
increasingly complex through the different steps of care. There is often a lack of information 
regarding specific treatment recommendations for older people with life limiting illness and 
multi-morbidity. While guidelines frequently explain how and when a medication should be 
initiated, there is often no information concerning when the medications should be reduced 
or stopped. Overall, this approach increases the potential for polypharmacy, the development 
of drug related events, and possible harm to patients. In view of this, it is important for future 
guideline development for specific conditions to holistically consider all aspects of medication 
utilisation, including how and when the medication should be reviewed, reduced, and 
stopped.  
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